A retrospective study analyzed clinical data from 171 NSCLC patients with EGFR mutations that were treated with anti-PD-1/PD-L1 alone or in combination with anti-CTLA-4. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.